France's Novacyt H1 revenue rises on Southern Cross Diagnostics acquisition

Novacyt SA

30/09/2026 07:25

Overview
France molecular diagnostics firm's H1 revenue rose 18% yr/yr to £11.6m
Gross margin fell to 56% from 66%, mainly due to SCD acquisition and lower Primer Design sales

Outlook
Novacyt expects continued organic revenue growth in H2, driven by Instrumentation and Clinical portfolios
Company anticipates further opex reductions in H2, with full annualised benefit seen in 2027
Novacyt expects Research Use Only segment buying patterns to normalise and uplift sales in H2

Result Drivers
SCD ACQUISITION - Revenue growth was partly driven by the acquisition of Southern Cross Diagnostics, which contributed £1.8m in sales but diluted group gross margin due to lower distributor margins and a stock uplift adjustment
CLINICAL SEGMENT GROWTH - The Clinical segment delivered over 20% year-on-year revenue growth, driven by demand for reproductive health products and inclusion of SCD sales
INSTRUMENTATION DEMAND - Instrumentation segment revenue grew about 30% year-on-year, reflecting continued market adoption of the LightBench Discover platform

Company press release: ID:nRSd8581Wa

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
H1 Adjusted EBITDA
 
-GBP 3.58 mln
 

Reuters Recommended Reads
Sept 29 - France's LightOn H1 revenue jumps 51% on higher Paradigm license sales
Sept 28 - France's Genfit H1 revenue falls due to absence of milestone payments 
Sept 29 - France's GenSight Biologics H1 net loss widens on higher R&D expenses

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)